OR WAIT 15 SECS
PopsiCube, the digital Clinical Research Organization, provides its pharmaceutical and health company sponsors with expertise in both clinical trial management and in digital services. This dual competency allows us to monitor phase I to IV clinical trials and develop innovative tools which are specific to the needs of our clients. In addition to providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry, PopsiCube is offering specific tailor made solutions and numerous applications in such fields as randomization, data capture, ePRO, eCOA, Patient Diary, biocaptors or data management, compliant with EMEA and FDA regulations and quality guidelines to facilitate the clinical development process. POPSICUBE is ISO 9001:2015 certified. In particular, we have developed an array of data capture solutions, from Digital Pen and Paper data capture, to eCRF, IVRS/IWRS and smartphone/tablet or biosensors solutions, allowing us to offer the technology that best matches the specificities of the clinical study protocol.
To be able to best support the growing demands of our worldwide customers, PopsiCube has decided to open a new affiliate in the Republic of Russia. The new company, PopsiCube Rus ooo, is based in Moscow. With this location, we also benefit from the presence of leading academic and research institutions in the Republic of Russia. It will allow us to support our growth objectives by establishing close relationships with our customers and by providing them with local, highly experienced management support for their projects.
“We are extremely excited by the creation of our Russian affiliate” commented Fabrice BeauchÃªne, PopsiCube Founder and Chairman, “Popsi Cube is experiencing a large growth (+62%) as the demand for our services and solutions is expanding rapidly within the health industry. We are committed to providing our sponsors with the highest level of service and we believe that proximity and internationalization is a critical element of our support. It will also allow us to more easily capitalize upon the large business opportunity represented by the Eurasian market.”